Effect of continuous IL-2 administration via the portal vein on growth of liver metastases and cytotoxicity of liver associated mononuclear cells in rats
        山口医学 Volume 39 Issue 3
        Page 401-411
        
published_at 1990-06
            Title
        
        門脈内IL-2持続投与による肝転移巣増殖の制御と肝臓内単核球の細胞傷害活性の増強
        Effect of continuous IL-2 administration via the portal vein on growth of liver metastases and cytotoxicity of liver associated mononuclear cells in rats
        
    
        
            Source Identifiers
        
    
        The aim of this study was no assess the effects of continuous administration of human recombinant interleukin- (rIL-2) via the portal vein on the induction of lymphokine-activated killer (LAK) activity of liver-associated mononuvlear cells, and on the therapeutic activity for hepatic metastases. Donryu rats (8-10 week, male) were inoculated with 1×10^6 AH130 allogenic tumor cells on day 0 via the portal vein, and 2 days later, rIL-2 (50,000 U/day) was administrated continuously via the portal vein (P group), or into the subcutaneous tissue(S group). Control rats were received saline alone (C group). On day 8, the incidence of liver metastases was assessed, and cytotoxisities of blood mononuclear cells (BMC), slenic cells (SC) and non-parenchymal cells of the liver (fraction 1 
        
        
            Languages
        
            jpn
    
    
        
            Resource Type
        
        journal article
    
    
        
            Publishers
        
            山口大学医学会
    
    
        
            Date Issued
        
        1990-06
    
    
        
            File Version
        
        Not Applicable (or Unknown)
    
    
        
            Access Rights
        
        metadata only access
    
    
            Relations
        
            
                
                
                [ISSN]0513-1731
            
            
                
                
                [NCID]AN00243156
            
    
        
            Schools
        
            医学部
    
                
